/
Rare Disease
Acromegaly
9
Pipeline Programs↗
6
Active Trials↗
13
Companies Involved↗
Acromegaly is an early-stage landscape with 9 programs across 13 companies. The most active players are CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marea Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
7 of 9 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.
Analysis
Trial Status
74
clinical trials
Completed52 · 70%
Terminated10 · 14%
Recruiting5 · 7%
Unknown status3 · 4%
Approved for marketing1 · 1%
Withdrawn1 · 1%
Other2 · 3%
Clinical Trials
Trial Activity
74 trials
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Completed·—·Phase 4·NCT00552071·15 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)